Identi Healthcare: Gross-Margin Quality, Inventory, and the Cash-Flow Gap
Identi's gross margin improved in 2025, but most of the gain came from system services and from deferring product cost through inventory build. At the same time, operating cash flow stayed negative, and the Innovation Authority line also helped clean up the reported picture.
The main article set up the broader point: 2025 looks like an improvement year, but not yet like a full proof year. This follow-up isolates one question only, and it is a critical one: how much of the gross-margin improvement really reflects better business economics, and how much rests on deferred cost and on accounting lines that never showed up in cash.
The thesis here is straightforward: Identi's margin did improve, but not every part of that improvement carries the same quality. The strongest layer is mix. System services rose to NIS 6.584 million and became 66.5% of revenue, so service gross profit expanded. The less clean layer sits in inventory. Hardware inventory jumped to NIS 3.13 million, and the inventory-change line reduced product cost of sales by NIS 1.126 million. A third layer sits below gross profit altogether. Net R&D expense benefited from the Innovation Authority line moving from a NIS 198 thousand expense in 2024 to NIS 289 thousand of income in 2025. Put that next to NIS 5.267 million of negative operating cash flow and the picture is much more complex than the headline "margin improved."
| Layer | 2024 | 2025 | What it means |
|---|---|---|---|
| Gross margin | 40.4% | 47.1% | A 6.7-point improvement, but the source matters |
| Gross profit from system services | NIS 2.948 million | NIS 3.654 million | Most of the improvement came from services |
| Gross profit from product sales | NIS 1.131 million | NIS 1.005 million | The hardware layer actually weakened |
| Hardware inventory | NIS 2.004 million | NIS 3.13 million | Up 56% ahead of expected sales growth |
| Operating cash flow | Negative NIS 4.016 million | Negative NIS 5.267 million | Cash did not validate the P&L improvement |
| Innovation Authority line inside net R&D expense | NIS 198 thousand expense | NIS 289 thousand income | A positive accounting swing of NIS 487 thousand in 2025 |
What really improved gross margin
Management's explanation in the directors' report is export growth and higher SaaS sales. That is directionally right, but incomplete. Once notes 17 and 18 are combined, the picture becomes clearer. System-services revenue rose to NIS 6.584 million from NIS 5.877 million, while service cost stayed almost flat at NIS 2.93 million versus NIS 2.929 million. That means service gross profit increased by NIS 706 thousand.
The product layer looks much less impressive. Product sales fell to NIS 3.314 million from NIS 4.212 million, and gross profit from product sales slipped to NIS 1.005 million from NIS 1.131 million. In other words, the full-year gross-profit improvement of NIS 580 thousand did not come from hardware. It came almost entirely from services. That matters because it means the margin improvement was driven mainly by a shift toward a more recurring revenue layer, not by a broad improvement across every operating engine.
Inventory carried the hardware story
This is the core of the continuation. Note 8 shows hardware inventory rising to NIS 3.13 million from NIS 2.004 million. The directors' report says that this increase reflects inventory build ahead of expected sales growth. That may well be true. But as long as that inventory has not yet been sold, part of the cost stays on the balance sheet instead of moving through the income statement.
Note 18 makes the mechanism visible. Under product sales, the materials-and-equipment line jumped to NIS 3.435 million from NIS 1.848 million, an increase of NIS 1.587 million. At the same time, the inventory-change line flipped from a NIS 1.233 million expense in 2024 to NIS 1.126 million of income in 2025. That is a NIS 2.359 million swing inside product cost of sales. As a result, recognized product cost fell to NIS 2.309 million from NIS 3.081 million even though procurement itself increased sharply.
That is the point a first read can easily miss. The hardware layer did not improve because equipment became cheaper to procure. The opposite happened. Procurement rose materially. What eased reported product cost was that part of the cost remained in inventory. That is why year-end hardware inventory was almost as large as the entire year's product revenue, NIS 3.13 million versus NIS 3.314 million, and already reached about 92% of year-end cash.
That does not automatically make inventory a problem. If 2026 brings the sales the company prepared for, the inventory build will look reasonable in hindsight. But until that happens, 2025 margin includes a deferred-cost component. That is exactly the difference between improvement in the report and improvement already proven in cash.
The cash-flow gap did not close
The right frame here is all-in cash flexibility. If the margin improvement were already high-quality, the first thing to look for would be at least some repair in cash generation. That did not happen. Operating cash flow worsened to negative NIS 5.267 million from negative NIS 4.016 million in 2024. One of the main drivers was the NIS 1.126 million inventory use. Lower receivables, worth NIS 1.213 million, offset part of that pressure, but not enough to change the overall picture.
The result is straightforward. Year-end cash stood at NIS 3.407 million, but that was not produced by gross profit alone. Investing activity consumed another NIS 451 thousand, while financing generated NIS 7.127 million, driven mainly by NIS 7.321 million of net equity issuance. In other words, cash ended the year higher because new capital covered the burn, not because the margin improvement had already translated into internally funded growth.
This gap matters because it says the 2025 gross-margin improvement still has not proven itself as cash generation. As long as the company is building inventory faster than it converts that inventory into sales, even a real accounting improvement in gross margin can come with a heavy working-capital cost.
The Innovation Authority also made the year look cleaner
A smaller but still meaningful layer sits below gross profit. In net R&D expense, the Innovation Authority liability line recorded NIS 289 thousand of income in 2025, versus NIS 198 thousand of expense in 2024. That is a positive swing of NIS 487 thousand inside the income statement. At the same time, the year-end liability to the Innovation Authority still stood at NIS 1.275 million, including NIS 127 thousand current and NIS 1.148 million long term.
This is not a contradiction. It is a reminder. That line does not explain gross-margin improvement, but it does help explain why the 2025 net loss looks cleaner than the cash picture. Put differently, not all of the improvement in the reported year came through customers, delivery, and cash. Part of it also came through an accounting mechanism tied to future royalty obligations.
Conclusion
Identi's 2025 gross-margin improvement is not fake, but it is not fully clean either. The higher-quality part came from system services becoming a larger share of revenue and lifting gross profit with almost no increase in direct cost. The less clean part sits in products: hardware inventory expanded, the inventory-change line eased cost of sales, and gross profit from product sales actually declined. Above that, operating cash flow remained more negative, and the Innovation Authority line also helped polish the reported year.
So the right read of 2025 is not "the margin has been fixed." It is "margin quality improved partly, while the cash-conversion test is still open." If 2026 brings lower inventory alongside higher product sales and better operating cash flow, then 2025 will look like a reasonable build year in hindsight. If not, part of the 2025 improvement will turn out to have pulled cost forward without yet solving the cash economics.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.